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Abstract Metastases are responsible for most cancer-related
deaths. One of the hallmarks of metastatic cells is increased
motility and migration through extracellular matrixes. These
processes rely on specific small GTPases, in particular those
of the Rho family. Deleted in liver cancer-1 (DLC1) is a tumor
suppressor that bears a RhoGAP activity. This protein is lost in
most cancers, allowing malignant cells to proliferate and
disseminate in a Rho-dependent manner. However, DLC1 is
also a scaffold protein involved in alternative pathways lead-
ing to tumor and metastasis suppressor activities. Recently,
substantial information has been gathered on these mecha-
nisms and this review is aiming at describing the potential and
known alternative GAP-independent mechanisms allowing
DLC1 to impair migration, invasion, and metastasis
formation.
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1 Introduction
Cancer remains the second leading cause of death worldwide
[1]. An almost irretrievable outcome of cancer is metastatic
progression [2]. Initiation of the metastatic cascade starts with
a cellular reprogramming called epithelial-to-mesenchymal
transition (EMT) that prompts malignant cells to escape the
primary tumor site by simultaneous loss of cell–cell contact and
gain of motility and invasiveness [3]. Control of motility is
therefore a crucial step for malignancy prevention. Migration
is finely tuned by pathways that modulate actin dynamics
and focal adhesion (FA) formation [4]. FAs are complex
multiprotein structures that allow attachment of the cell with
the extracellular matrix (ECM) and that transduce various sig-
naling pathways [5]. Small GTPases of the Rho family are
major regulators of actin dynamics and FA formation [6]; their
deregulation may therefore lead to tumorigenesis [7]. There are
more than 60 members in the Rho family. Among these, Rho
itself, Rac, and Cdc42 are the best characterized proteins that
regulate the cytoskeleton during migration [8]. Rho controls the
formation of actin stress fibers through actomyosin bundling
and contraction [9]. Rac and Cdc42 are responsible for actin
polymerization leading to formation of two kinds of protru-
sions: filopodia and lamellipodia. Filopodia, which require the
formation of long actin filaments, are controlled by Cdc42.
These structures participate in environment sensing and direc-
tional migration. Lamellipodia, which are large and branched
actin network protrusions, are controlled by Rac [9].
Small GTPases, including those from the Rho family, cycle
between an inactive GDP-bound state and an active GTP-
bound conformation. In their active form, they modulate cell
signaling by interacting with effector proteins [10]. Activation
of small GTPases is performed by guanine nucleotide ex-
change factors (GEFs) that catalyze the exchange of GDP
for GTP. Small GTPase inactivation, on the other hand, is
performed by GTPase-activating proteins (GAPs) that in-
crease the low intrinsic GTP-hydrolysis activity of the small
GTPases. There are 67 GAPs that modulate the Rho family
GTPase members [11]. Intuitively, it could have been antici-
pated that loss of function mutations or epigenetic silencing of
many of these GAPs would occur during carcinogenesis, yet
only one of them, deleted in liver cancer-1 (DLC1), has been
found to be widely downregulated in tumors [12].
DLC1 (also known as p122RhoGAP, ARHGAP7, and
STARD12) is a RhoGAP protein with tumor and metastasis
suppressor activities [13] that has been shown to be mutated
almost as often as p53 in cancer [14]. DLC1 has been exten-
sively investigated for its role as a tumor suppressor (reviewed
in [13, 15–17]) and during migration (reviewed in [18]). It is
now known that DLC1 expression prevents cell migration
[19–24], invasion [23, 24] and metastatic progression
[25–27] in various cancer types. There is accumulating
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evidence that DLC1 exerts some of its functions in a
GAP-independent manner by interacting with a series of
newly identified partners. This review aims at describing
the role of DLC1 during cell migration and metastatic pro-
gression with a particular emphasis on its GAP-independent
functions.
2 Deleted in liver cancer-1
The deleted in liver cancer (DLC) protein family is composed
of DLC1, DLC2, and DLC3. Members of this small family
share high similarity and functional redundancy [13]. They all
are GTPase activating proteins. The DLC family members
contain a steroidogenic acute regulatory protein-related lipid-
transfer (StART) domain and hence belong to a larger group
of proteins called the StART family [17].
DLC2 and DLC3 are thought to function similarly as
DLC1; they remain however much less studied than DLC1
[13]. Yet the observation that DLC2-null mice are viable in
opposition to DLC1-null mice that die in utero indicate that
the different DLC isoforms are not performing fully overlap-
ping functions [28].
DLC1 was first identified in 1995 in the rat and was
named p122RhoGAP [29]. The human orthologue was
cloned and described 3 years later by the laboratory of Nich-
olas C. Popescu [30]. It has a wide expression in mouse and
human (brain, heart, kidney, liver, lung and skin, etc.) [30,
31]. DLC1 harbors potent GAP activities towards RhoA,
B and C, a more limited GAP activity towards Cdc42, but
it does not regulate the GTPase activity of Rac1 [26, 32]. Rho
and Cdc42 inactivation limits cell survival responses and also
prevents cell migration by inducing actin stress fiber disrup-
tion [8]. DLC1 is also a platform protein that interacts with
several partners, which modulates their activity in a GAP-
independent manner.
First discovered as a tumor suppressor that was lost in
hepatocarcinomas [30], DLC1 was later found to be down-
regulated in several other malignancies including hematolog-
ical malignancies, and lung, breast, prostate, kidney, colon,
uterus, ovary, and stomach cancers [13, 33]. Importantly,
DLC1 was found to be as frequently mutated as p53 in most
aggressive cancers [12, 14], which may not come as a surprise
since Rho activation is required for tumor progression and for
full transformation by oncogenes such as Ras [7, 34]. Loss of
DLC1 expression is associated with high metastatic potential
[35]. In humans, deletion of the short arm of chromosome 8,
which contains the dlc1 gene, is a frequent event associated
with cancer development [14, 36]. More targeted mutations of
the dlc1 gene leading to reduced expression of the protein
were also reported such as exonic missense mutations and
intronic insertions/deletions in primary ovarian and colorectal
cancers [37]. DLC1 can also be epigenetically silenced [38,
39]. In liver, breast, colon and prostate cancers, this results
from hypermethylation of the CpG island in the DLC1 pro-
moter [38]. In some tumors, like those of the prostate, loss of
DLC1 is mostly carried out by epigenetic silencing and not a
consequence of gene mutations [39]. Acetylation also modu-
lates DLC1 activity since treatment of several cancer types
with the histone deacetylase inhibitor trichostatin A
reactivates DLC1 expression [39]. DLC1 is also the target of
several kinases including protein kinase A (PKA), Akt/PKB,
PKC and PKD [40–43]. Phosphorylation of DLC1 on serine
567 by Akt and on serines 327 and 431 by PKC lead to
inhibition of its GAP activity [40, 42].
Initially, the tumor suppressor function of DLC1 was at-
tributed to its GAP activity on Rho [12, 14]. This notion was
derived from observations such as that DLC1 silencing or
expression of a constitutively active form of RhoA induced
comparable accelerating effects on liver tumor growth [14].
However, GAP-independent mechanisms may also be in-
volved in the tumor suppressive function of DLC1. Indeed,
reintroduction of a GAP-dead DLC1 mutant in small cell lung
cancer cells that did not express DLC1 impaired colony for-
mation in soft agar, although to a lower extent than wild-type
DLC1 [26]. Another observation supporting the GAP-
independent tumor suppressive function of DLC1 is that ec-
topic expression of a GAP-dead DLC1 mutant in NIH3T3
fibroblasts partially abrogated migration [44]. Also in this
case, expression of the wild-type DLC1 led to a stronger
inhibition of migration. It is therefore likely that DLC1 uses
both GAP-dependent and GAP-independent mechanisms to
exert its tumor suppressive effects.
The question as to why DLC1 is the only RhoGAP, out of
67, that is lost in malignancies has been raised [12]. Possibly,
DLC1, but not other RhoGAPs, prevents the activation of a
non-canonical Rho pathway that would be specifically re-
quired for transformation. A more likely possibility to us is
that it is the GAP-independent functions of DLC1 that
strengthen its tumor suppressor activities. This does not mean
that the other RhoGAPs do not have GAP-independent activ-
ities, some in fact do [45, 46], but presumably their GAP-
independent activities are not involved in counteracting
tumorigenesis.
2.1 DLC1 structures
DLC1 interacts with its partners through conserved domains:
a sterile alpha motif (SAM) domain, a GAP domain, a StART
domain and a serine-rich (SR) region (Fig. 1). These domains
are also found in the other members of the DLC family. SAM
domains (amino acid 11 to 78 in human DLC1) are almost as
frequently found are almost as frequently found in proteins as
SH2 domains [45]. SAM domains display great functional
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diversity. They can bind to one another, they can associate
with non-SAM domains, and they can interact with RNA,
lipid molecules, etc. [45]. SAM domains may be involved in
the dimerization capacity of DLC1 [43]. The middle part of
DLC1 contains a serine-rich unstructured and relatively poor-
ly conserved region with numerous potential sites for tyrosine
phosphorylation (amino acids 86 to 638). Within this central
part lie two highly conserved motifs: (a) the LD motif (amino
acids 469 to 476) that is known to be essential for DLC1
binding to FAK and talin, two proteins associated with focal
adhesion [46], and (b) a binding site for tensin proteins
(amino acids 440 to 445; more specifically tyrosine 442).
The GAP domain (amino acids 639 to 847) is highly con-
served between the three DLC isoforms and displays selec-
tive GAP activity towards RhoA, B, and C, and Cdc42 [26].
Two arginine residues within the GAP domain, R677 and
R718, are crucial for DLC1 GAP activity, most likely by
acting as “arginine fingers” [46, 47]. The C-terminal part of
DLC1 is occupied by a StART domain (amino acids 878 to
1081). StART domains are conserved ∼210 amino acid se-
quence forming a hydrophobic pocket that can bind lipids
such as cholesterol [48]. However, no role in lipid transport
has been reported for the DLC family. The physiological
functions of the DLC1 StART domain remain relatively
elusive at this point. However, interaction partners have been
identified for each domain/region of DLC1, including the
StART domain (Fig. 1), suggesting that these sequences play
important roles in DLC1’s functions.
2.2 Differential DLC1 expression levels
Varying DLC1 expression has an impact on focal adhesions,
actin dynamics and the migratory capacity of the cells. DLC1
is reduced, or even lost, in many tumors and this, based on the
capacity of DLC1 to regulate cell migration, may affect the
metastatic potential of malignant cells [49]. It is indeed well
accepted that diminished DLC1 levels during tumorigenesis
results in more motile and invasive cell behavior [14].
Accordingly, RNA interference-mediated DLC1 reduction in
cancer cells promoted increased migration [19]. On the other
hand, restoring DLC1 expression in cancer cells that had
down-regulated DLC1 led to inhibition of migration and
invasion, particularly in breast cancer [25, 50],
hepatocarcinoma [23], multiple myeloma [24], and colon
cancer [51]. Experimental overexpression of DLC1 resulted
in disruption of focal adhesion, cell shrinkage and loss of
stress fibers [22, 23, 47]. However, absence of DLC1 may
also compromise cytoskeleton dynamics and migration. For
example, silencing DLC1 in normal prostate epithelial cells
inhibited their migration [52]. Additionally, DLC1 knock-
out fibroblasts display disrupted stress fibers and fewer
focal adhesions [53]. Therefore, overexpression and total
absence of DLC1 may both compromise proper cytoskele-
ton dynamics and migration, while reduced expression of
DLC1 could favor migration. Consequently, inhibition of
DLC1 in malignant cells with reduced expression of the
protein may represent a therapeutical approach to prevent
metastasis development.
3 Molecular basis of migration and metastasis
Cell migration is physiologically required during develop-
ment, wound healing and immune responses, among others
[54]. Its deregulation is involved in several pathological con-
ditions such as metastatic progression and lissencephaly [54,
55]. Cell migration involves spatiotemporally regulated
events that can be divided into four main steps [9]: (a) polar-
ization of the cell, (b) formation of protrusion and adhesion
structures, (c) contraction of the cell body, and (d) retraction of
the cell rear. In order to move, cells have to create new actin
filaments that push the plasma membrane forward and depo-
lymerize actin filaments at the cell rear [56]. Actin dynamics is
a highly complex phenomenon involving dozens of proteins.
How actin polymerization and depolymerization is achieved
has been reviewed in details elsewhere [4, 57]. The Rho
Fig. 1 DLC1 binding partners. The domains of DLC1 are represented by
colored rectangles . Interactions with binding partners are indicated.
DLC1 phosphorylation sites are indicated by P-containing circles and
labeled as follows: green circle for GAP-inhibiting phosphorylations,
blue circles for GAP-activating phosphorylations, and red circles for
phosphorylations that trigger DLC1 GAP-independent effects
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GTPases, in particular Rho, Rac, and Cdc42, play pivotal
roles during the four processes mentioned above. Cdc42 es-
tablishes cell polarity by controlling the localization of the
Golgi apparatus. Cdc42 also triggers filopodia formation [58].
Rac controls the generation of lamellipodia and is also respon-
sible for early nascent focal contact formation [6]. Rho par-
ticipates in the formation of FAs and stress fibers [59]. In
addition, Rho triggers acto-myosin contraction that allows cell
movement and tail retraction [8]. Inactivation of Rho, Rac,
and Cdc42 abrogates migration [58, 60].
Metastasis occurs when malignant cells, often in response
to stresses such as those resulting from gamma irradiation
[61], undergo epithelial-mesenchymal transition (EMT). This
process consists in changes in cell morphology that will be
required for a cell to migrate in its extracellular environment
[62]. EMT is characterized by the loss of E-cadherins [63],
and hence loss of cell-cell adhesion structures, but also by
increased expression of proteins involved in cell migration
such as the Rho GTPases. Studies performed with dominant
negative mutants and constitutively active forms of Rho, Rac
and Cdc42 revealed that all three proteins are indispensable
for migration into the extracellular matrix [64, 65]. Overex-
pression of RhoA increases invasiveness and is often detected
in metastatic tumors [66, 67]. RhoB-null mouse embryonic
fibroblasts display impaired motility and adhesion due to
lower expression levels of the β1-integrin adhesion receptor
[68]. Studies on the RhoC knock-out mouse and analyses on
highly metastatic melanoma cells revealed that RhoC is re-
quired for the metastatic process, but it is not involved in
cancer cell proliferation [69, 70]. RhoC favors tumor dissem-
ination through sequential activation of Pyk2, a focal adhesion
tyrosine kinase, FAK,MAP kinases, Akt, and the upregulation
of the MMP-2 and MMP-9 matrix metalloproteinases [71].
When Rho and Cdc42 are in the active GTP-bound form,
they interact with several effectors known to directly affect
cytoskeleton dynamics [9, 72]. Rho in particular modulates
actin dynamics through ROCK activation [73]. ROCK facil-
itates acto-myosin contraction by inhibiting the myosin light
chain (MLC) phosphatase and by directly phosphorylating
MLC. Accumulation of phosphorylated MLC leads to actin
bundling and contraction, and the formation of stress fibers.
ROCK also has the ability to phosphorylate the LIM kinase
(LIMK) that in turn phosphorylates and inactivates ADF/
cofilin, leading to actin filament stabilization [4]. Rho controls
actin polymerization in at least two different ways. First, Rho-
mediated activation of the mDia formins leads to actin nucle-
ation and elongation [74]. Second, activated Rho binds and
activates phosphatidylinositol-4-phosphate 5-kinase (PIP ki-
nase), which leads to accumulation of phosphatidylinositol
4,5-bisphosphate (PIP2) [9], which in turn promotes actin
polymerization (discussed in detail below).
When activated, Cdc42 binds and stimulates several effec-
tors that positively regulate actin polymerization and hence
migration [75]. Cdc42 interacts with PAK1 and activates it
leading to LIMK stimulation, cofilin inactivation and there-
fore prevention of actin depolymerization [9]. In addition,
Cdc42 has the ability to stimulate WASP, which results in
actin polymerization via activation of the Arp2/3 nucleator
[75]. Cdc42 controls the orientation of the microtubule-
organizing center (MTOC) that defines the positioning of the
Golgi apparatus that is required for directed migration [76].
Cdc42 has recently been shown to increase trans-endothelial
migration by modulating β1-integrin expression level and
activity [77].
4 DLC1 role in migration and invasion
4.1 What is regulated by the GAP activity of DLC1?
As discussed before, DLC1 has GAP activity towards RhoA,
B, and C, and, albeit with lower potency, towards Cdc42 [26].
The negative effect of DLC1 on Cdc42, initially demonstrated
in vitro [26], was recently corroborated in vivo [32]. The
physiological consequences of this modulation still remain
to be established though. Inactivation of RhoA by DLC1
results in loss of stress fibers and focal adhesions [22]. This
can negatively impact on the ROCK pathway as shown in
hepatocellular carcinoma where DLC1 prevents phosphoryla-
tion of MLC [78]. As indicated previously, DLC1 silencing
increases Rho activity and favors migration. However, ROCK
is not necessarily involved in this response. Indeed, DLC1
silencing in breast cancer increases migration in a mDia1-
dependent but ROCK-independent manner [50]. Yet, the tu-
mor suppressor activity of DLC1 still appears to depend on
ROCK since colony formation induced by DLC1 silencing is
abrogated upon treatment with the Y-27632 ROCK inhibitor
[14]. Participation of other Rho effectors that are inhibited by
Y-27632, like citron kinase and PKN [79], cannot be excluded
however. Possibly, ROCK inhibition by DLC1 contributes to
its tumor growth suppressive function, while inhibition ofmDia
formins by DLC1 leads to a migration suppressor activity.
In addition to regulating the canonical Rho pathway, DLC1
is controlling adherens junction (AJ) stability [80]. AJs are
structures that mediate cell-to-cell interactions and consist in
complexes between the transmembrane E-cadherin protein
and cytoplasmic p120 catenin and β-catenin [81]. By binding
to β-catenin, α-catenin can be recruited to the AJ, which then
leads to the attachment of the actin cytoskeleton to E-
cadherins. This favors the maturation and the stability of AJs
[82, 83]. Loss of E-cadherin and α-catenin destabilizes AJs, a
situation often documented during metastasis formation when
tumor cells are no longer linked to one another, favoring their
dissemination [63]. DLC1 binds to α-catenin and allows its
interaction with AJs. This requires the GAP activity of DLC1
[80]. The presence of DLC1 in AJs contributes to its
Cancer Metastasis Rev (2014) 33:87–10090
oncosuppressive activity and reinforces AJ stability. DLC1-
mediated inhibition of RhoA and RhoC has been shown to
promote expression of E-cadherin, increasing the number of
AJs and strengthening cell–cell interactions [84]. It is now
well accepted that decreased AJ stability is associated with
increased motility and dissemination during EMT [63]. The
consequence of the DLC1-mediated effects on AJ remains
however to be directly evaluated during cell migration and
invasion. Nevertheless, it remains quite clear that DLC1,
through its negative regulation of Rho and Cdc42, via its
GAP domain, contributes to inhibition of cell migration and
invasion [4].
DLC1 carries many potential phosphorylation sites in par-
ticular in its serine-rich region. Akt- and PKD-mediated phos-
phorylation of DLC1 can negatively affect its GAP activity
[40, 42]. PKD-mediated phosphorylation on serines 327 and
431 allows DLC1 to bind six out of the seven isoforms of the
14-3-3 scaffold protein family [40]. This binding sequesters
DLC1 in the cytoplasm away from FAs, preventing it to fulfill
its tumor and metastasis suppressor functions. Other phos-
phorylation events induce reverse effects. Very recently, the
cyclic AMP-dependent kinase PKAwas shown to phosphor-
ylate DLC1 on serines 431 and 549. This induced DLC1
dimerization and enhancement of its GAP activity, leading
to increased oncosuppressive effects and inhibition of migra-
tion, invasion and metastasis formation [43]. The GAP activ-
ity of DLC1 can therefore be differentially tuned by phos-
phorylation events.
The next section will discuss how DLC1 can also exert
anti-metastatic activity independently of its GAP activity.
4.2 DLC1 GAP-independent signaling
Eleven DLC1 interacting proteins and four kinases that phos-
phorylate DLC1 have been described so far; these are listed in
Table 1. Some of these interactions may modulate the GAP
activity of DLC1 but may also result in DLC1 GAP-
independent signaling and modulation of the DLC1-binding
partner activity. The interaction map of DLC1 with other
proteins is shown in Fig. 1. The relevance of these interactions
is discussed below.
4.2.1 PLCδ1 and phosphoinositide signaling
Phosphoinositides are phosphorylated forms of phos-
phatidylinositol, a phospholipid found in cellular membranes.
Phosphoinositides comprise phosphatidyl-inositol (PI) phos-
phate (PIP), PI bisphosphate (PIP2), or PI trisphosphate
(PIP3). These molecules act as secondary messengers, and as
scaffold and signaling molecules [92]. The phospholipase C
proteins have the ability to hydrolyze the ester bond between
the glycerol and the phosphate group and can therefore trans-
form PIP2 into inositol triphosphate (IP3) and diacyglycerol
(DAG) [92]. The first discovered binding partner of DLC1
was phospholipase lipase C delta 1 (PLCδ1). By binding to
PLCδ1, DLC1 enhances its hydrolyzing activity resulting in
Table 1 DLC1-interacting partners
Protein Binding site (aa) Effect on DLC1 Effect on the target Ref.
PLCδ1 StART domain Not investigated + (increased activity) [29]
Tensin 440–445 + (GAP); FA localization − (β-integrin binding inhibition) [85–88]
Talin 469–476 (LD motif; SR) + (GAP); FA localization Not investigated [46]
FAK 469–476 (LD motif; SR) + (GAP); FA localization Not investigated [46]
S100A10 348–354 No effect (GAP) − (degradation) [89]
Caveolin-1 929–957 (StART) No effect (GAP), Caveolae localization − (Caveolin-1 dynamics) [90]
EF1A1 38–39 (SAM) No effect (GAP) Membrane recruitment [44]
p120-RasGAP 798–847 (GAP) − (GAP) Not investigated [91]
PTEN SAM Not investigated + (increased activity) [21]
14-3-3 S327 and S431 (SR) − (GAP); sequestration Not investigated [40]
α-catenin 340–435 (SR) + (GAP); AJ localization + (AJ stability) [80]
Kinase Phosphorylation site (aa) Effect on DLC1 Effect on the target Ref.
PKA S431 and S549 (SR) + (GAP) Not investigated [43]
Akt/PKB S567 (SR) − (GAP) Not investigated [42]
PKC/PKD S327 and S431 (SR) − (GAP) Not investigated [40]
PKD S807 (GAP) No effect (GAP); + (GAP-independent) Not investigated [41]
This table lists the DLC1-interacting partners and the effects of the indicated interaction on DLC1 and the concerned binding partner. Positive and
negative modulation of DLC1 are indicated by the + and − symbols, respectively
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increased IP3 and DAG levels and a corresponding decrease of
PIP2. The consequence of this enzymatic reaction on the
cytoskeleton is complex (reviewed in [92]). PIP2 establishes
a linkage between the actin cytoskeleton and the membrane
and stimulates actin polymerization through several routes
[92, 93]. It primarily helps actin translocation to the plasma
membrane where most actin polymerization proteins are lo-
calized [93]. It stimulates the WASP protein that in turn
activates Arp2/3, an actin nucleator that allows the formation
of protrusions pushing the membrane forward [4]. PIP2 binds
to several other actin regulators. By binding to the gelsolin
capping protein, PIP2 disrupts the actin/gelsolin complex.
This leads to uncapping of the actin filament barbed end (also
called the plus end), hence favoring actin polymerization [94].
Profilin is a protein that interacts with monomeric actin for
delivery to the polymerizing barbed-ends of actin filaments
[4]. PIP2 then binds to profilin which dissociates from actin
allowing the latter to be incorporated on the growing actin
fiber. PIP2 is also required for the conformational activation of
vinculin and talin, two focal adhesion proteins the activation
of which allows cell attachment, a step required for efficient
migration.
Although PLCδ1 was the first identified DLC1 binding
partner, the nature of their interaction has still not been fully
determined although the GAP-StART domain region appears
to be important (see Fig. 1) [29]. The interaction of PLCδ1 and
DLC1 takes place at focal adhesions where DLC1 co-localizes
with vinculin [95]. This localization is consistent with its
potential role during migration. Interestingly, as DLC1,
PLCδ1 has been defined as a tumor suppressor and inhibitor
of migration [96]. Several approaches involving injection of
PIP2 or overexpression of negative regulators of PIP2 have led
to the notion that increasing PIP2 levels results in actin poly-
merization while decreasing PIP2 levels leads to actin depo-
lymerization [92]. One can anticipate that the decrease of PIP2
levels through DLC1-mediated activation of PLCδ1 is a pos-
sible Rho-independent mechanism allowing DLC1 to modu-
late cytoskeleton dynamics and cell movement. The biological
relevance of the DLC1/PLCδ1 interaction on migration re-
mains however to be evaluated.
4.2.2 DLC1 and focal adhesion regulation
DLC1 can be found in several subcellular structures [80, 90, 95]
but location at focal adhesions is the one most often reported
[21, 22, 44, 46, 50, 85–88, 95, 97–101]. What is commonly
called focal adhesions actually comprise all types of anchorage
contacts. These are, from smallest to biggest/longest, focal
contacts (FXs), focal adhesions (FAs), and fibrillar adhesions
(FBs) [102].When integrins are engaged by their ECM ligands,
talin and paxillin are quickly recruited to form the FXs, which
are transient adhesive structures. FXs that are not turned over
transform into FAs by recruiting proteins such as FAK,
vinculin, α-actinin, and zyxin, and this provides an anchorage
point to link actin bundles. FBs are much longer and stronger
adhesive structures that are localized in central areas under the
cell and that are characterized by the presence of tensins. The
tensin family is composed of four members, tensin-1, tensin-2,
tensin-3, and C-terminal tensin-like (cten) [103]. Tensins are
often downregulated in cancer, in particular in metastasis, sug-
gesting that they play tumor and metastasis suppressor func-
tions [103]. By linking the actin cytoskeleton and most of the
integrin cytoplasmic tails (β1, β3, β5, and β7-integrins),
tensins provide a crucial function required for cell migration
[103–106].
DLC1 was reported to interact with each tensin family
member [85–88]. The binding mode of DLC1 with the tensin
proteins is however complex as it seems to vary between
different tensin isoforms. The first identified binding mode
involves the DLC1 SH2-binding motif containing serine 440
and tyrosine 442 (Fig. 1) and the SH2 domain of tensin-1 and
cten. This binding does not require phosphorylation of tyro-
sine residues though [87]. Other binding modes have been
unraveled recently, including interaction of the 374 to 388
DLC1 sequence with the phosphotyrosine-binding (PTB) do-
main of tensin-2 [99] and the actin-binding motif of tensin-3
[88]. The latter contains a region, lacking in cten, that binds
the DLC1 SAM domain [88]. DLC1-tensin binding occurs at
focal adhesions where DLC1 most likely acts as a tumor [86,
87] and migration [98] suppressor. Interestingly, mutational-
driven disruption of this binding prevents DLC1 FA localiza-
tion and abrogates its oncosuppressive activity, without neg-
atively impinging on its GAP activity [46, 87]. When fused to
a FA binding domain, the DLC1 mutant that is unable to bind
tensins relocalizes to FBs but only partially recovers its tumor
suppressor activity. Thus, the GAP activity at FBs does not
appear to fully mediate some given DLC1 biological activi-
ties. DLC1 was reported to compete with β3-integrin for
binding with tensin-1 [86]. As a result, DLC1 engagement to
tensin-1 prevents the connection between integrins and
tensins. Since localization of tensins to FBs, where they
interact with integrins, is crucial for establishing the anchorage
points used by cells to move [105], this inhibitory function of
DLC1 would be one of the means it can use to impede cell
migration. Thus DLC1 can negatively regulate migration by
competing with tensins for integrin binding independently of
its Rho GAP activity. How this competition is regulated is
only partially understood.
FAK and talin are two other FA proteins that can interact
with DLC1 [46]. Talin, like tensins, can directly interact with
integrins, while FAK mediates the link between talin and the
actin cytoskeleton [5]. An eight amino acid motif within
DLC1, called LD-motif (amino acids 469 to 476), is respon-
sible for this binding. DLC1 can interact simultaneously with
talin and FAK [46]. Potentially, this increases the capacity of
DLC1 to translocate to FAs, which, as mentioned earlier, is the
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place where DLC1 is supposed to exert its oncosuppressive
functions. Paxillin is another focal adhesion protein that binds
to FAK through its fourth LD motif [107]. DLC1 was shown
to displace paxillin from FAK [46]. Interestingly, cells over-
expressing a truncated version of paxillin that lacks the fourth
LD motif display dramatically decreased migration [108].
While the effects of DLC1 binding on the structure of FAs
have not yet been evaluated, one could predict that DLC1
binding to FAK negatively affects focal adhesion turnover and
therefore migration by displacing paxillin from FAK. This
represents yet another GAP-independent mechanism by
which DLC1 inhibits migration and invasion.
4.2.3 The plasminogen connection
The urokinase plasminogen activator (uPA) and tissue plas-
minogen activator (tPA) are activated upon binding to the
uPAR membrane receptors. They then convert plasminogen
into plasmin, a serine protease that degrades the ECM. They
also stimulate matrix metalloproteinases (MMPs) that partic-
ipate in ECM degradation [109]. The plasminogen activator
inhibitor-1 (PAI-1) is a serine protease inhibitor that negative-
ly regulates uPA and tPA. PAI-1 binds to uPA/tPA and leads to
their internalization, preventing uPA/tPA to convert plasmin-
ogen into plasmin [110, 111]. PAI-1 also directly inhibits the
MMP activity, as well as the αvβ3-integrin binding to
vitronectin, two crucial processes during invasion [112]. The
S100A10 protein is a cell surface receptor and a plasminogen
activator. It competes with PAI-1 to bind to uPA/tPA. This
results in augmented plasmin production and promotion of
invasiveness. S100A10 has also the ability to directly bind
plasmin and activate its auto-proteolysis.
DLC1 modulates the plasminogen pathway to prevent dis-
semination. DLC1 binds to S100A10, increasing its suscepti-
bility to ubiquitin-dependent degradation and this potently re-
duces, in a GAP-independent manner, S100A10-mediated plas-
minogen activation [89]. The binding to S100A10 occurs
through the 348-354 DLC1 sequence. RNAi-mediated silenc-
ing of S100A10 in lung cancer cells leads to reduced colony
formation and impaired invasiveness, as DLC1 does [89].
Another study investigating the role of DLC1 on the plasmin-
ogen pathway reported an unexpected effect of DLC1 on
migration [52]. In this study, silencing DLC1 in human prostate
epithelial cells led to increased PAI-1 expression that resulted in
migration inhibition. Conversely DLC1 overexpression de-
creased PAI-1 expression levels. The reason of this discrepancy
(i.e., DLC1/PAI-1 favors migration in lung cancer while it
inhibits it in normal prostate cells) is unclear but may depend
on the transformation status of a cell or possible differences in
DLC1 residual expression after silencing.
ECM integrity and composition are often affected in meta-
static contexts [113, 114]. While certain ECM components are
upregulated to favor motility, others are lost or degraded by
MMPs allowing dissemination [114, 115]. A study revealed
that DLC1-mediated inhibition of liver metastasis formation
was associated with the downregulation of the ECM compo-
nent osteopontin, and the MMP-9 matrix metalloproteinase
[27]. Osteopontin and MMP-9 have been associated with inva-
sive phenotypes [115, 116]. Therefore, this is a potential alter-
native way for DLC1 to prevent metastasis formation. DLC1
has been shown to shuttle between the nucleus and the cyto-
plasm [40]. Although its function in the nucleus is not known, it
is possible that DLC1 regulates the activity of transcription
factors. This could be the basis of the DLC1-mediated repres-
sion of MMP-9 and osteopontin transcription.
4.2.4 DLC1 in caveolae
Caveolae are specialized plasma membrane subdomains that
are involved in vesicular transport and compartmentalization
of signaling proteins. Caveolin-1 is a major caveolae compo-
nent, driving their formation and linking them to the cytoskel-
eton [117]. These organelles play an important role during
adhesion and migration in several ways [117]. Caveolin-1
binds to filamin, an actin-binding protein linking stress fibers
at integrin sites and controling their stability. Caveolae pro-
mote adhesion, migration and invasion by interacting with and
stabilizing uPAR and αV-integrin [118] (see previous section).
Stable knock-down of caveolin-1 induces decreased β1-
integrin-dependent adhesion and disruption of the caveolin-
1/β1-integrin complex inhibits migration [118]. Caveolae also
play a role during invasion by favoring plasminogen activa-
tion and by hosting the MMP-2 [119]. Another evidence for
the involvement of caveolae duringmigration is their ability to
control calcium release at the cell rear which is required for
calcium-dependent protease-mediated cleavage of focal adhe-
sion proteins [120].
In 2004, the rat DLC1 orthologue and caveolin-1 were
reported to colocalize in caveolae and to interact through the
DLC1 GAP domain [121]. DLC1 interaction with caveolin-1
leads to both internalization of DLC1 and caveolae. The
physiological importance of caveolin-1-DLC1 interaction
was recently evaluated and the mapping of this interaction
was revisited. It was found that the human DLC1 StART
domain was responsible for this interaction rather than the
previously reported rat DLC1 GAP domain [90]. Stable ex-
pression of a DLC1mutant that was unable to bind caveolin-1
in DLC1-negative lung cancer cells failed, unlike the wild-
type DLC1, to inhibit colony formation, tumor migration into
transwells, and in vivo tumor growth. Importantly, this DLC1
mutant retained a full GAP activity on RhoA, demonstrating
that the migration inhibitory effect of DLC1 was either GAP-
independent or that the DLC1 GAP activity needs to be
brought to caveolae. How the DLC1/caveolin-1 interaction
inhibits migration is however not fully understood. One can
hypothesize however that DLC1 and caveolae internalization
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prevents DLC1 from exerting a Rho GAP activity at the
leading edge of the cell. Together with a decreased number
of caveolae structures at the plasma membrane, this would be
expected to markedly hamper cell migration.
4.2.5 The SAM binders
In contrast to most DLC1 partners that interact with the SR
and C-terminal DLC1 regions, EF1A1 and PTEN bind to the
N-terminal SAM domain (Fig. 1). EF1A1 (for eukaryotic
elongation factor 1A1) is involved in protein translation.
EF1A1 also binds to the actin cytoskeleton and regulates its
dynamics through several mechanisms, independently from
its role in protein synthesis, by (a) it can bind to and bring β-
actin mRNA at protrusion sites (i.e., plasma membrane sec-
tions that are pushed out by growing actin fibers) [122], (b)
through its actin-bundling activity [123], and (c) by binding to
G-actin and possibly sequestering it [124]. EF1A1 binds to the
38–40 sequence of DLC1 within the SAM domain [44]. This
interaction seems to be an important GAP-independent event
controlling cell migration since transfection of a DLC1mutant
unable to bind EF1A1 but with an unaffected GAP activity
induces a weaker migration inhibitory effect than the wild-
type construct in fibroblasts. An interpretation that cannot be
excluded though is that the DLC1 GAP activity needs to be
located at the exact same place where EF1A1 lies. It was
suggested that the SAM domain and the GAP domain of
DLC1 can interact and this is believed to generate an auto-
inhibitory signal. Indeed, the GAP domain of DLC1 is 20
times more active when isolated than when embedded in full-
length DLC1 [22, 26]. Consistent with these observations is
that overexpression of the SAM domain induces a higher
motility rate than full-length DLC1. Instead, overexpression
of a SAM construct that does not bind EF1A1 did not stimu-
late migration [44]. This indicates that modulation of migra-
tion by the DLC1 SAM domain depends on its ability to bind
EF1A1, possibly in a GAP-independent manner.
The phosphatase and tensin homolog (PTEN), a tumor
suppressor, also binds to the DLC1 SAM domain [21]. This
binding was proposed to mediate PTEN-induced dephosphor-
ylation of FAK, leading to migration inhibition. However this
hypothesis remains to be formally proven. Tensin-3 binds the
DLC1 SAM domain through its actin-binding domain, the
consequence of which is thought to release the SAM auto-
inhibitory effect on GAP activity. The GAP-independent im-
plications of tensin-DLC1 interaction are discussed above.
4.2.6 GAP-to-GAP
GAPs and GEFs rarely modulate a single GTPase. This is the
case with DLC1 that regulate both Rho and Cdc42. Moreover,
different GAPs and GEFs can modulate the same GTPase.
This considerably increases the complexity of small GTPase
regulation [10]. Additionally, binding between different GAPs
has been reported. For instance, p120 RasGAP and p190
RhoGAP interact and this is believed to control, on the one
hand, the accessibility of the RasGAP SH3 domain and, on the
other hand, the GAP activity of p190 [125, 126]. Interestingly
the RasGAP SH3 domain was shown to bind the DLC1 GAP
domain resulting in inactivation of the latter’s GAP activity
[91] and consequently this should increase cell motility. We
recently discovered that the 317–326 amino acid sequence
within the SH3 of RasGAP mediates its binding to DLC1
[134]. Treatment of cells with a cell-permeable version of the
peptide corresponding to these 10 amino acids, the so-called
TAT-RasGAP317–326 peptide, resulted in increased adhesion
associated with a potent inhibition of migration and invasion.
This was an unexpected observation because, assuming that
this peptide functions as the SH3 domain of RasGAP, it should
also inhibit the GAP activity of DLC1 and hence favors
migration. However, treatment with the C3 exoenzyme and
Y-27632, which are inhibitors of Rho and ROCK, respective-
ly, did not reverse this phenotype, suggesting that the RasGAP
peptide exerts its activity in a DLC1 GAP-independent man-
ner. Although the mechanisms induced by the RasGAP pep-
tide downstream of DLC1 remain to be elucidated, this re-
flects once more the importance of GAP-independent events
in the DLC1-mediated control of migration.
4.2.7 DLC1 phosphorylation
The serine/threonine kinase PKD phosphorylates DLC1 on
serine 807 that lies within its GAP domain. This phosphoryla-
tion was reported to increase the inhibitory effect of DLC1 on
colony formation and cell migration without modulating the
GTP-bound state of RhoA [41]. Phosphorylation of DLC1 can
therefore potentially inhibit dissemination and tumor growth in
a GAP-dependent as well as in a GAP-independent manner.
The in vivo relevance of PKD-mediated S807 phosphorylation
remains however to be investigated.
5 Discussion
DLC1 is convincingly more than just a GAP for small
GTPases of the Rho family; it is also a scaffolding protein
that triggers a wide range of signaling responses affecting cell
survival and controlling cell motility. Specific down-
regulation of DLC1may be used by malignant cells to survive
and become metastatic. Together with the two well-
established cancer associated proteins BRCA1 and HIF1-α,
loss of DLC1 has recently been recognized as a biomarker for
early stage lung adenomarcinomas [127]. Therapeutic strate-
gies aimed at restoring DLC1 expression represent an attrac-
tive anti-cancer strategy and this indeed has already been
attempted. Using demethylation-inducing agents or dietary
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flavones, DLC1 expression could be restored in cell lines in
which it was epigenetically silenced and this hampered pro-
liferation and induced cell cycle arrest [128]. In vivo antican-
cer responses resulting from epigenetic restoration were how-
ever not reported [128]. Rho isoforms are often overexpressed
in cancer. Reactivating DLC1 in cancers would be interesting
in this context since two distinct anticancer signaling would be
triggered; those that dependent on the GAP activity of DLC1
and those that do not. These two effects would hopefully
synergize or at least be additive. Our recent data obtained with
TAT-RasGAP317–326 [134] indicate that DLC1-targeted
druggable compounds with anti-metastatic potential can be
generated.
Figure 2 summarizes schematically the potential different
GAP-independent mechanisms presented in this review. The-
se include actin depolymerization (via PLCδ1 inhibition), FA
remodeling (via interaction with tensins, FAK and talin),
plasminogen production inhibition (via S100A10 degrada-
tion), caveolin internalization, and RasGAP and EF1A1-
dependent anti-metastatic signaling. Such responses, in par-
ticular if happening simultaneously, could induce potent inhi-
bition of migration and invasion.
Although not discussed in this review, DLC2 and DLC3
can add an additional layer of complexity to this picture.
Overexpression of DLC2 was shown to induce loss of stress
fibers and inhibit cancer cell growth [129, 130]. Similarly,
DLC2 loss is associated with enhanced migration [131].
DLC2 associates with mitochondria [132] and interacts with
α-tubulin [129], two features that are not shared with DLC1.
Interestingly, DLC2 seems to bear some activity towards Rac
and could therefore synergize with DLC1, which does not
regulate Rac, in preventing migration [133]. Akin to DLC1,
DLC3 is a focal adhesion tumor suppressor broadly lost in
various malignancies (reviewed in [17]) but its functions are
Fig. 2 DLC1 GAP-independent anti-metastatic mechanisms. This scheme highlights the anti-metastatic mechanisms used by DLC1 with a special
emphasis on the GAP-independent signaling events. See main text for details
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not well understood at the moment. GAP-independent signal-
ing has not been reported for DLC2 and 3 but it would not be
surprising that the mechanisms mentioned in this review are
also used by them.
There is a wealth of data supporting the notion that normal
or increased DLC1 expression levels inhibit migration or
invasion, while decreased DLC1 expression favors these pro-
cesses. Intriguing data challenge however this simple view.
For example DLC1-null fibroblasts display a complete loss of
stress fibers [53]. As stress fibers are required for migration,
cell movement should be inhibited, contradicting the idea that
DLC1 suppresses invasion. In addition, DLC1 silencing in
normal prostate cells leads to migration inhibition, the oppo-
site of what is usually found in the literature [52]. Intriguingly,
these two studies reporting a pro-migratory role of DLC1were
performed in non-malignant cells. Modulation of DLC1 ex-
pression levels in normal and cancer cells may therefore not
have the same consequence. We recently generated data that
also challenge the simple view that DLC1 loss favors migra-
tion. We found out that the TAT-RasGAP317–326 peptide
inhibited migration in a large panel of normal and malignant
cells but failed to have this effect in DLC1-null mouse em-
bryonic fibroblasts [134]. DLC1 was expressed to very low,
sometimes undetectable, levels in some of the cancer cells
used in this study but TAT-RasGAP317–326 was nevertheless
still able to inhibit their migration. Here again, the conse-
quence of DLC1 loss may differ between malignant cells
and the normal mouse embryonic fibroblasts. Alternatively,
complete (as in knock-out DLC1 cells) or partial (as in cancer
cells) DLC1 loss may not necessarily lead to the same migra-
tory phenotype. It will be very important in the future to solve
this conundrum.
In conclusion, DLC1 contributes to growth and migratory
suppressive effects through GAP-dependent and GAP-
independent mechanisms. In contrast to what have been pro-
posed previously, the GAP-independent mechanism may ful-
fill important tumor suppressor functions and represent there-
fore potential avenues of research to develop new anti-cancer
therapies.
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